Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences : to Present New Oncotype DX Genomic Prostate Score« Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting

09/02/2021 | 07:42pm EST
Exact Sciences to Present New Oncotype DX Genomic Prostate Score® Test Data and Exhibit its Full Urology Portfolio at the 2021 Virtual AUA Annual Meeting
By Exact Sciences / September 02, 2021

MADISON, Wis., September 2, 2021 - Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the companywill present new data and exhibit its portfolio of prostate cancer genomic tests at its virtual booth, during the American Urological Association's Annual (AUA 2021) Meeting, being held September 10-13. This is the first AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urology genomic assays, including the Oncotype DX Genomic Prostate Score® (GPS™) test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer. An analysis of the SEER registrypresented at the meetingwill reinforce the value of the Oncotype DX® GPS test in helping guide treatment decisions in clinically low-risk prostate cancer patients.

'With clinical outcomes data across 15 publications and in more than 5,000 men, the Oncotype DX GPS test is one of the most rigorously studied assays in localized prostate cancer. The data we're presenting at AUA once again highlight its clinical utility in helping physicians and patients decide between active surveillance and definitive treatment,' said Rick Baehner, chief medical officer of Precision Oncology for Exact Sciences. 'We're also thrilled to showcase our entire prostate cancer portfolio, supporting early to late-stage patient care, while connecting with our collaborators in the urology and oncology community.'

Key AUA activities featuring the Oncotype portfolio during the meeting include:

Disclaimer

EXACT Sciences Corporation published this content on 02 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 September 2021 23:41:06 UTC.


ę Publicnow 2021
All news about EXACT SCIENCES CORPORATION
11/23Exact Sciences Says New Data in Clinically Low-Risk Prostate Cancer Patients Backs Use ..
MT
11/23New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predicto..
PR
11/23Exact Sciences Corporation Announces Publication of Results Underscoring the Importance..
CI
11/18Exact Sciences Partners With Jefferson Health on Multi-Cancer Earlier Detection Test Re..
MT
11/18Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Dete..
PR
11/18Exact Sciences and Jefferson Health Commence Collaboration on Multi-Cancer Earlier Dete..
CI
11/04NORTH AMERICAN MORNING BRIEFING : Stocks Futures -3-
DJ
11/03INSIDER SELL : Exact Sciences
MT
11/03BTIG Adjusts Exact Sciences' Price Target to $120 From $145, Reiterates Buy Rating
MT
11/03Wells Fargo Adjusts Price Target on Exact Sciences to $95 From $120, Maintains Equal-We..
MT
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 735 M - -
Net income 2021 -520 M - -
Net Debt 2021 1 330 M - -
P/E ratio 2021 -28,4x
Yield 2021 -
Capitalization 14 918 M 14 918 M -
EV / Sales 2021 9,36x
EV / Sales 2022 8,21x
Nbr of Employees 4 900
Free-Float 99,3%
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 86,57 $
Average target price 129,35 $
Spread / Average Target 49,4%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
EXACT SCIENCES CORPORATION-35.50%14 726
GUARDANT HEALTH, INC.-17.04%10 869
BGI GENOMICS CO., LTD.-27.94%5 733
INVITAE CORPORATION-56.97%4 072
ADAPTIVE BIOTECHNOLOGIES CORPORATION-52.44%3 969
SEEGENE, INC.-22.28%3 112